Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Rises By 1,478.5%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,910,000 shares, an increase of 1,478.5% from the March 15th total of 121,000 shares. Approximately 11.6% of the shares of the company are sold short. Based on an average daily volume of 2,810,000 shares, the days-to-cover ratio is presently 0.7 days.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Oppenheimer increased their price objective on shares of Sensei Biotherapeutics from $3.50 to $4.00 and gave the stock an “outperform” rating in a research note on Friday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a report on Friday, March 28th.

Sensei Biotherapeutics Stock Up 19.3 %

Shares of SNSE opened at $0.46 on Wednesday. Sensei Biotherapeutics has a 52 week low of $0.25 and a 52 week high of $1.94. The stock has a market cap of $11.55 million, a price-to-earnings ratio of -0.38 and a beta of 0.21. The business has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.48.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its earnings results on Friday, March 28th. The company reported ($0.27) EPS for the quarter, hitting analysts’ consensus estimates of ($0.27). On average, equities analysts anticipate that Sensei Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. XTX Topco Ltd grew its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,903 shares of the company’s stock after buying an additional 48,977 shares during the period. XTX Topco Ltd owned 0.25% of Sensei Biotherapeutics worth $31,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.